REVANCE THERAPEUTICS INC (RVNC)

US7613301099 - Common Stock

12.09  -0.33 (-2.66%)

After market: 12.09 0 (0%)

REVANCE THERAPEUTICS INC

NASDAQ:RVNC (9/27/2023, 7:00:02 PM)

After market: 12.09 0 (0%)

12.09

-0.33 (-2.66%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)08-08 2023-08-08/amc
Earnings (Next)11-06 2023-11-06/amc
Ins Owners1.56%
Inst Owners93.91%
Market Cap1.06B
Shares87.96M
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts82.22
IPO02-06 2014-02-06
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Growth Stock Screener

Find more growth stocks the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

RVNC Daily chart

Company Profile

Revance Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The company is headquartered in Nashville, Tennessee and currently employs 534 full-time employees. The company went IPO on 2014-02-06. The firm is focused on advanced aesthetic and therapeutic offerings. The Company’s aesthetics portfolio of expertly created products and services, including DAXXIFY (DaxibotulinumtoxinA-lanm) for injection, the RHA Collection of dermal fillers, and OPUL, the first-of-its-kind relational commerce platform for aesthetic practices. The Company’s therapeutics pipeline is focused on muscle movement disorders, including evaluating DAXXIFY in two debilitating conditions, cervical dystonia and upper limb spasticity. The DaxibotulinumtoxinA for Injection combines a proprietary stabilizing peptide excipient along with the other excipients. DAXXIFY a commercially approved product, is an acetylcholine release inhibitor and neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients.

Company Info

REVANCE THERAPEUTICS INC

1222 Demonbreun Street, Suite 2000

Nashville TENNESSEE 37203

P: 16157247755.0

CEO: Mark J. Foley

Employees: 534

Website: https://www.revance.com/

RVNC News

News Image8 days ago - Market News VideoNotable Tuesday Option Activity: UEC, MNTK, RVNC
News Image8 days ago - ChartmillWhich stocks are experiencing notable movement on Tuesday?

Wondering how the US markets performed one hour before the close of the markets on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis.

News Image9 days ago - ChartmillWhich stocks are moving on Tuesday?

Intrigued by the market activity in the middle of the day on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.

News Image9 days ago - Investor's Business DailyFormer IBD 50 Stock Revance Implodes As Its 'Prestige' Plan Goes Up In Smoke

The company is still figuring out how to gain share in a market topped by AbbVie.

News Image9 days ago - ChartmillThese stocks are gapping in today's session

Let's have a look at what is happening on the US markets on Tuesday. Below you can find the gap up and gap down stocks in today's session.

News Image9 days ago - Revance Therapeutics, Inc.Revance Provides Corporate Update at Investor Day

RVNC Twits

Here you can normally see the latest stock twits on RVNC, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example